DNA-aptamer targeting vimentin for tumor therapy in vivo.
暂无分享,去创建一个
Darija Muharemagic | Yury E. Glazyrin | Y. Glazyrin | O. Kolovskaya | M. Berezovski | A. Zamay | M. Wehbe | A. Salmina | Anna S Zamay | Maxim V Berezovski | Olga S Kolovskaya | Anna G Savitskaya | Galina S Zamay | Xiaoyan Wang | Mohamed Wehbe | Alla B Salmina | Olga A Zubkova | Ekaterina A Spivak | Yury E Glazyrin | S. Kuznetsova | Tatyana N Zamay | Svetlana A Kuznetsova | Anastasia Kadkina | Anna Dubynina | Yuliya Sheina | Yu. I. Sheina | O. Zubkova | Xiaoyan Wang | Darija Muharemagic | G. Zamay | A. Savitskaya | T. N. Zamay | E. Spivak | A. Kadkina | A. Dubynina | Mohamed Wehbe | Anna G. Savitskaya
[1] M. Roehrl,et al. Glycoproteomic Analysis of Human Lung Adenocarcinomas Using Glycoarrays and Tandem Mass Spectrometry: Differential Expression and Glycosylation Patterns of Vimentin and Fetuin A Isoforms , 2009, The protein journal.
[2] Q. Shen,et al. RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells , 2009, Oncogene.
[3] Daniel G. Anderson,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[4] P. V. van Diest,et al. The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? , 2005, The Journal of pathology.
[5] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[6] Sergey N Krylov,et al. Aptamer-facilitated biomarker discovery (AptaBiD). , 2008, Journal of the American Chemical Society.
[7] A. Al-Hendy,et al. Gene therapy and uterine leiomyoma: a review. , 2006, Human reproduction update.
[8] Ofer Levy,et al. Systemic Stimulation of TLR2 Impairs Neonatal Mouse Brain Development , 2011, PloS one.
[9] Xiaoling Zhang,et al. Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells , 2009, Chembiochem : a European journal of chemical biology.
[10] Xun Sun,et al. A cell-specific poly(ethylene glycol) derivative with a wheat-like structure for efficient gene delivery. , 2012, Molecular pharmaceutics.
[11] H. Kijima,et al. Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. , 2010, Biomedical research.
[12] Johanna Ivaska,et al. Novel functions of vimentin in cell adhesion, migration, and signaling. , 2007, Experimental cell research.
[13] A. Ellington,et al. Inhibition of Cell Proliferation by an Anti-EGFR Aptamer , 2011, PloS one.
[14] D. Xie,et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis , 2004, Oncogene.
[15] Yury E. Glazyrin,et al. Development of bacteriostatic DNA aptamers for salmonella. , 2013, Journal of medicinal chemistry.
[16] Y. Sakaki,et al. Refined human artificial chromosome vectors for gene therapy and animal transgenesis , 2010, Gene Therapy.
[17] R. Juliano,et al. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides , 2008, Nucleic acids research.
[18] B. Stefanovic,et al. A Novel Role of Vimentin Filaments: Binding and Stabilization of Collagen mRNAs , 2011, Molecular and Cellular Biology.
[19] J. Pin,et al. Immature Human Dendritic Cells Express Asialoglycoprotein Receptor Isoforms for Efficient Receptor-Mediated Endocytosis1 , 2001, The Journal of Immunology.
[20] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[21] Andrea Rentmeister,et al. Cell-Specific Aptamers as Emerging Therapeutics , 2011, Journal of nucleic acids.
[22] J. Brooks,et al. CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma , 2009, BMC clinical pathology.
[23] Kwangmeyung Kim,et al. Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo. , 2013, Molecular pharmaceutics.
[24] H. Ulrich. RNA aptamers: from basic science towards therapy. , 2006, Handbook of experimental pharmacology.
[25] S. Shukla,et al. Cytokeratin and Vimentin Expression in Breast Cancer , 2009 .
[26] D. Liggitt,et al. Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[27] Dexi Liu,et al. Computer-assisted hydrodynamic gene delivery. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] Anthony D. Keefe,et al. Aptamers as therapeutics , 2010, Nature Reviews Drug Discovery.
[29] Darija Muharemagic,et al. Electrochemical differentiation of epitope-specific aptamers. , 2012, Analytical chemistry.
[30] G. Christman,et al. Gene therapy and reproductive medicine. , 2002, Fertility and sterility.
[31] C. Lehr,et al. Lectins and glycoconjugates in drug delivery and targeting. , 2004, Advanced drug delivery reviews.
[32] Y. Barenholz,et al. Polymers for DNA Delivery , 2005, Molecules.
[33] F. Chen,et al. Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis , 2001, Cell Death and Differentiation.
[34] Y. Nakagawa,et al. CpG island promoter methylation (CIHM) status of tumor suppressor genes correlates with morphological appearances of gastric cancer. , 2010, Anticancer research.
[35] Baocun Sun,et al. A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis , 2010, Journal of experimental & clinical cancer research : CR.
[36] L. Wiebe,et al. Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. , 2008, Current drug delivery.
[37] M. Mann,et al. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.
[38] Darija Muharemagic,et al. Anti-Fab aptamers for shielding virus from neutralizing antibodies. , 2012, Journal of the American Chemical Society.
[39] J. Foidart,et al. Transactivation of Vimentin by β-Catenin in Human Breast Cancer Cells , 2003 .
[40] A. Ellington,et al. In Vitro Selection of RNA Aptamers to a Small Molecule Target , 2002, Current protocols in nucleic acid chemistry.
[41] A. Satelli,et al. Vimentin in cancer and its potential as a molecular target for cancer therapy , 2011, Cellular and Molecular Life Sciences.
[42] P. Ray,et al. Aptamers for Targeted Drug Delivery , 2010, Pharmaceuticals.
[43] Wei Chen,et al. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. , 2010, American journal of translational research.
[44] L. Josephson,et al. Arabinogalactan for hepatic drug delivery. , 1994, Bioconjugate chemistry.
[45] N. Hu,et al. Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer , 2004, Oncogene.
[46] X. Long,et al. Vimentin affects the mobility and invasiveness of prostate cancer cells , 2008, Cell biochemistry and function.
[47] R. Narain,et al. Intracellular delivery of DNA and enzyme in active form using degradable carbohydrate-based nanogels. , 2012, Molecular pharmaceutics.
[48] Michael Wirth,et al. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. , 2004, Advanced drug delivery reviews.
[49] M. Yashiro,et al. Clinical significance of vimentin-positive gastric cancer cells. , 2010, Anticancer research.
[50] H. Herschman,et al. Asialoglycoprotein receptor mediates the toxic effects of an asialofetuin-diphtheria toxin fragment A conjugate on cultured rat hepatocytes. , 1981, Proceedings of the National Academy of Sciences of the United States of America.